Related Experiment Video

Updated: Apr 16, 2026

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:45

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

356

RNA-targeted Therapeutics for ALS

Linga V Reddy1, Timothy M Miller

  • 1Department of Neurology, Washington University, 660 S. Euclid, St. Louis, MO, 63110, USA.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|March 11, 2015
PubMed

Insights

Amyotrophic lateral sclerosis (ALS) treatments face challenges in slowing disease progression. RNA inhibition strategies, like small interfering RNA, show promise for genetic ALS forms due to available research and models.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron loss.
  • Current therapeutic strategies for ALS have limited success in halting disease advancement.
  • Genetic factors play a significant role in a subset of ALS cases.

Purpose of the Study:

  • To explore the potential of RNA-targeted therapeutic approaches for treating amyotrophic lateral sclerosis (ALS).
  • To evaluate the feasibility of using RNA inhibition strategies in the context of ALS genetics and available models.

Main Methods:

  • Investigated small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) as potential therapeutic agents.
  • Leveraged existing knowledge of causative genes in ALS.
  • Considered data from a phase 1 clinical trial.

Main Results:

  • RNA inhibition strategies are being developed for genetic forms of ALS.
  • The study highlights ALS as a suitable candidate for RNA-targeted therapies.
  • Progress in understanding causative genes and a phase 1 trial provide a foundation.

Conclusions:

  • RNA-targeted therapies, including siRNA and ASOs, represent a promising avenue for genetic ALS.
  • The well-defined nature of ALS genetics and available models support the development of these RNA inhibition strategies.

More Related Videos

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis13:31

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

9.3K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
89.5K